Semaglutide is a GLP-1 receptor agonist (glucagon-like peptide-1), which mimics a hormone in your body responsible for regulating blood sugar levels and controlling appetite
Key Takeaways CJC-1295 is a GHRH analog: It binds to GHRH receptors in the pituitary to stimulate growth hormone release Ipamorelin is a GHRP (ghrelin mimetic): It binds to GHS-R1a receptors via a completely different pathway Different mechanisms make them complementary: Published research often examines their combination due to non-competing receptor targets Neither is FDA-approved: Both remain research compounds not intended for human therapeutic use Combination protocols appear in published literature: Studies by Bowers et al
Patients with pattern hair loss sometimes see stabilization or regrowth of density
References Gasmi A, Nasreen A, Lenchyk L, Lysiuk R, Peana M, Shapovalova N, Piscopo S, Komisarenko M, Shanaida M, Smetanina K, Antonyak H, Fira L, Lykhatskyi P, Fira D, Bjrklund G
These glutathione mono-alkyl esters are substituted at the glycine residue and employ alkyl chains having only 1 to 10 carbons
In simpler terms, estrogen amplifies some of the metabolic effects that GLP-1 medications produce